Global Exocrine Pancreatic Insufficiency Market 2018 by Manufacturers, Countries, Type and Application, Forecast to 2023

  • receipt Report ID : 144871
  • calendar_today Published On: Apr, 2019
  • file_copy Pages: 130
  • list Pharmaceuticals and Healthcare

Exocrine pancreatic insufficiency (EPI) is an inability of proper digestion of food owing to insufficient levels of digestive enzymes from pancreas.

Scope of the Report:

This report studies the Exocrine Pancreatic Insufficiency market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Exocrine Pancreatic Insufficiency market by product type and applications/end industries.

EPI is commonly found in humans affected with Shwachman-Diamond Syndrome and cystic fibrosis. EPI is triggered by the progressive loss of pancreatic cells, which generates the digestive enzymes. EPI disturbs the normal growth, life expectancy and immune response. Diarrhoea, Steatorrhea, fatigue and weight loss are the key symptoms of EPI.

The global Exocrine Pancreatic Insufficiency market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.

The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.

North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Exocrine Pancreatic Insufficiency.

Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.

Market Segment by Companies, this report covers

Axcan Pharma

Aptalis Pharma

Eli Lilly

Cilian

Nordmark Arzneimittel

Laboratoires Mayoly Spindler

Market Segment by Regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers

Nutritional management

Pancreatic enzyme replacement therapy (PERT)

Life style modifications approach

Market Segment by Applications, can be divided into

Nutritional management

Pancreatic enzyme replacement therapy (PERT)

Life style modifications approach

Frequently Asked Questions

The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.

Market is segmented on the basis:

  • By Type
  • By Application
  • By Region
  • By Country
  • By Manufacturer

The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.

The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.

Table of Contents

1 Exocrine Pancreatic Insufficiency Market Overview

1.1 Product Overview and Scope of Exocrine Pancreatic Insufficiency

1.2 Classification of Exocrine Pancreatic Insufficiency by Types

1.2.1 Global Exocrine Pancreatic Insufficiency Revenue Comparison by Types (2017-2023)

1.2.2 Global Exocrine Pancreatic Insufficiency Revenue Market Share by Types in 2017

1.2.3 Nutritional management

1.2.4 Pancreatic enzyme replacement therapy (PERT)

1.2.5 Life style modifications approach

1.3 Global Exocrine Pancreatic Insufficiency Market by Application

1.3.1 Global Exocrine Pancreatic Insufficiency Market Size and Market Share Comparison by Applications (2013-2023)

1.3.2 Nutritional management

1.3.3 Pancreatic enzyme replacement therapy (PERT)

1.3.4 Life style modifications approach

1.4 Global Exocrine Pancreatic Insufficiency Market by Regions

1.4.1 Global Exocrine Pancreatic Insufficiency Market Size (Million USD) Comparison by Regions (2013-2023)

1.4.1 North America (USA, Canada and Mexico) Exocrine Pancreatic Insufficiency Status and Prospect (2013-2023)

1.4.2 Europe (Germany, France, UK, Russia and Italy) Exocrine Pancreatic Insufficiency Status and Prospect (2013-2023)

1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Exocrine Pancreatic Insufficiency Status and Prospect (2013-2023)

1.4.4 South America (Brazil, Argentina, Colombia) Exocrine Pancreatic Insufficiency Status and Prospect (2013-2023)

1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Exocrine Pancreatic Insufficiency Status and Prospect (2013-2023)

1.5 Global Market Size of Exocrine Pancreatic Insufficiency (2013-2023)

2 Manufacturers Profiles

2.1 Axcan Pharma

2.1.1 Business Overview

2.1.2 Exocrine Pancreatic Insufficiency Type and Applications

2.1.2.1 Product A

2.1.2.2 Product B

2.1.3 Axcan Pharma Exocrine Pancreatic Insufficiency Revenue, Gross Margin and Market Share (2016-2017)

2.2 Aptalis Pharma

2.2.1 Business Overview

2.2.2 Exocrine Pancreatic Insufficiency Type and Applications

2.2.2.1 Product A

2.2.2.2 Product B

2.2.3 Aptalis Pharma Exocrine Pancreatic Insufficiency Revenue, Gross Margin and Market Share (2016-2017)

2.3 Eli Lilly

2.3.1 Business Overview

2.3.2 Exocrine Pancreatic Insufficiency Type and Applications

2.3.2.1 Product A

2.3.2.2 Product B

2.3.3 Eli Lilly Exocrine Pancreatic Insufficiency Revenue, Gross Margin and Market Share (2016-2017)

2.4 Cilian

2.4.1 Business Overview

2.4.2 Exocrine Pancreatic Insufficiency Type and Applications

2.4.2.1 Product A

2.4.2.2 Product B

2.4.3 Cilian Exocrine Pancreatic Insufficiency Revenue, Gross Margin and Market Share (2016-2017)

2.5 Nordmark Arzneimittel

2.5.1 Business Overview

2.5.2 Exocrine Pancreatic Insufficiency Type and Applications

2.5.2.1 Product A

2.5.2.2 Product B

2.5.3 Nordmark Arzneimittel Exocrine Pancreatic Insufficiency Revenue, Gross Margin and Market Share (2016-2017)

2.6 Laboratoires Mayoly Spindler

2.6.1 Business Overview

2.6.2 Exocrine Pancreatic Insufficiency Type and Applications

2.6.2.1 Product A

2.6.2.2 Product B

2.6.3 Laboratoires Mayoly Spindler Exocrine Pancreatic Insufficiency Revenue, Gross Margin and Market Share (2016-2017)

3 Global Exocrine Pancreatic Insufficiency Market Competition, by Players

3.1 Global Exocrine Pancreatic Insufficiency Revenue and Share by Players (2013-2018)

3.2 Market Concentration Rate

3.2.1 Top 5 Exocrine Pancreatic Insufficiency Players Market Share

3.2.2 Top 10 Exocrine Pancreatic Insufficiency Players Market Share

3.3 Market Competition Trend

4 Global Exocrine Pancreatic Insufficiency Market Size by Regions

4.1 Global Exocrine Pancreatic Insufficiency Revenue and Market Share by Regions

4.2 North America Exocrine Pancreatic Insufficiency Revenue and Growth Rate (2013-2018)

4.3 Europe Exocrine Pancreatic Insufficiency Revenue and Growth Rate (2013-2018)

4.4 Asia-Pacific Exocrine Pancreatic Insufficiency Revenue and Growth Rate (2013-2018)

4.5 South America Exocrine Pancreatic Insufficiency Revenue and Growth Rate (2013-2018)

4.6 Middle East and Africa Exocrine Pancreatic Insufficiency Revenue and Growth Rate (2013-2018)

5 North America Exocrine Pancreatic Insufficiency Revenue by Countries

5.1 North America Exocrine Pancreatic Insufficiency Revenue by Countries (2013-2018)

5.2 USA Exocrine Pancreatic Insufficiency Revenue and Growth Rate (2013-2018)

5.3 Canada Exocrine Pancreatic Insufficiency Revenue and Growth Rate (2013-2018)

5.4 Mexico Exocrine Pancreatic Insufficiency Revenue and Growth Rate (2013-2018)

6 Europe Exocrine Pancreatic Insufficiency Revenue by Countries

6.1 Europe Exocrine Pancreatic Insufficiency Revenue by Countries (2013-2018)

6.2 Germany Exocrine Pancreatic Insufficiency Revenue and Growth Rate (2013-2018)

6.3 UK Exocrine Pancreatic Insufficiency Revenue and Growth Rate (2013-2018)

6.4 France Exocrine Pancreatic Insufficiency Revenue and Growth Rate (2013-2018)

6.5 Russia Exocrine Pancreatic Insufficiency Revenue and Growth Rate (2013-2018)

6.6 Italy Exocrine Pancreatic Insufficiency Revenue and Growth Rate (2013-2018)

7 Asia-Pacific Exocrine Pancreatic Insufficiency Revenue by Countries

7.1 Asia-Pacific Exocrine Pancreatic Insufficiency Revenue by Countries (2013-2018)

7.2 China Exocrine Pancreatic Insufficiency Revenue and Growth Rate (2013-2018)

7.3 Japan Exocrine Pancreatic Insufficiency Revenue and Growth Rate (2013-2018)

7.4 Korea Exocrine Pancreatic Insufficiency Revenue and Growth Rate (2013-2018)

7.5 India Exocrine Pancreatic Insufficiency Revenue and Growth Rate (2013-2018)

7.6 Southeast Asia Exocrine Pancreatic Insufficiency Revenue and Growth Rate (2013-2018)

8 South America Exocrine Pancreatic Insufficiency Revenue by Countries

8.1 South America Exocrine Pancreatic Insufficiency Revenue by Countries (2013-2018)

8.2 Brazil Exocrine Pancreatic Insufficiency Revenue and Growth Rate (2013-2018)

8.3 Argentina Exocrine Pancreatic Insufficiency Revenue and Growth Rate (2013-2018)

8.4 Colombia Exocrine Pancreatic Insufficiency Revenue and Growth Rate (2013-2018)

9 Middle East and Africa Revenue Exocrine Pancreatic Insufficiency by Countries

9.1 Middle East and Africa Exocrine Pancreatic Insufficiency Revenue by Countries (2013-2018)

9.2 Saudi Arabia Exocrine Pancreatic Insufficiency Revenue and Growth Rate (2013-2018)

9.3 UAE Exocrine Pancreatic Insufficiency Revenue and Growth Rate (2013-2018)

9.4 Egypt Exocrine Pancreatic Insufficiency Revenue and Growth Rate (2013-2018)

9.5 Nigeria Exocrine Pancreatic Insufficiency Revenue and Growth Rate (2013-2018)

9.6 South Africa Exocrine Pancreatic Insufficiency Revenue and Growth Rate (2013-2018)

10 Global Exocrine Pancreatic Insufficiency Market Segment by Type

10.1 Global Exocrine Pancreatic Insufficiency Revenue and Market Share by Type (2013-2018)

10.2 Global Exocrine Pancreatic Insufficiency Market Forecast by Type (2018-2023)

10.3 Nutritional management Revenue Growth Rate (2013-2023)

10.4 Pancreatic enzyme replacement therapy (PERT) Revenue Growth Rate (2013-2023)

10.5 Life style modifications approach Revenue Growth Rate (2013-2023)

11 Global Exocrine Pancreatic Insufficiency Market Segment by Application

11.1 Global Exocrine Pancreatic Insufficiency Revenue Market Share by Application (2013-2018)

11.2 Exocrine Pancreatic Insufficiency Market Forecast by Application (2018-2023)

11.3 Nutritional management Revenue Growth (2013-2018)

11.4 Pancreatic enzyme replacement therapy (PERT) Revenue Growth (2013-2018)

11.5 Life style modifications approach Revenue Growth (2013-2018)

12 Global Exocrine Pancreatic Insufficiency Market Size Forecast (2018-2023)

12.1 Global Exocrine Pancreatic Insufficiency Market Size Forecast (2018-2023)

12.2 Global Exocrine Pancreatic Insufficiency Market Forecast by Regions (2018-2023)

12.3 North America Exocrine Pancreatic Insufficiency Revenue Market Forecast (2018-2023)

12.4 Europe Exocrine Pancreatic Insufficiency Revenue Market Forecast (2018-2023)

12.5 Asia-Pacific Exocrine Pancreatic Insufficiency Revenue Market Forecast (2018-2023)

12.6 South America Exocrine Pancreatic Insufficiency Revenue Market Forecast (2018-2023)

12.7 Middle East and Africa Exocrine Pancreatic Insufficiency Revenue Market Forecast (2018-2023)

13 Research Findings and Conclusion

14 Appendix

14.1 Methodology

14.2 Data Source

List of Tables and Figures

Figure Exocrine Pancreatic Insufficiency Picture

Table Product Specifications of Exocrine Pancreatic Insufficiency

Table Global Exocrine Pancreatic Insufficiency and Revenu

Please fill the form below, to recieve the report sample


+1

Choose License Type

Reach Us

Email us at

sales@mrinsights.biz

Or call us on

US +1-201-465-4211

IND +91-906-779-0957

Why Choose Us

ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems

Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system

Global Outreach6 Major regions and 40+ countries level analysis accomplished

Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery